HIV drug maker gets SEC's 'goat' in insider trading scam
This article was originally published in Scrip
Executive Summary
Executives of a small publicly traded biotech in San Diego, California, got the US government's goat after routinely authorizing public securities filings that told investors "tall tales" about the status of the company's single drug candidate that was far different from reality, Securities and Exchange Commission (SEC) officials said, in charging those company managers with fraud and insider trading.